Supplementary Table 6. TEAEs of special interest

|  | Safety population ( $\mathrm{N}=932$ ) (Weeks 0-116) |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \text { IXE Q4Wa } \\ \mathrm{N}=454 \end{gathered}$ |  | $\begin{gathered} \hline \text { IXE Q2W }{ }^{\mathbf{a}} \\ \mathrm{N}=518 \end{gathered}$ |  |
|  | n (\%) | $\begin{gathered} \hline \text { IR (95\% CI) } \\ \text { PY=713.3 } \\ \hline \end{gathered}$ | n (\%) | $\begin{gathered} \text { IR (95\% CI) } \\ \text { PY }=885.6 \end{gathered}$ |
| Opportunistic infections | $\begin{gathered} 13 \\ (2.9) \\ \hline \end{gathered}$ | $\begin{gathered} 1.8 \\ (1.1,3.1) \\ \hline \end{gathered}$ | $\begin{gathered} 13 \\ (2.5) \\ \hline \end{gathered}$ | $\begin{gathered} 1.5 \\ (0.9,2.5) \\ \hline \end{gathered}$ |
| Candidiasis ${ }^{\text {b }}$ | $\begin{gathered} 7 \\ (1.5) \end{gathered}$ | $\begin{gathered} 1.0 \\ (0.5,2.1) \end{gathered}$ | $\begin{gathered} 4 \\ (0.8) \end{gathered}$ | $\begin{gathered} 0.5 \\ (0.2,1.2) \end{gathered}$ |
| Herpes simplex | 0 | $\begin{gathered} 0.0 \\ (0.0,1.1) \end{gathered}$ | $\begin{gathered} 3 \\ (0.6) \\ \hline \end{gathered}$ | $\begin{gathered} 0.3 \\ (0.1,1.1) \\ \hline \end{gathered}$ |
| Herpes zoster | $\begin{gathered} 6 \\ (1.3) \\ \hline \end{gathered}$ | $\begin{gathered} 0.8 \\ (0.4,1.9) \end{gathered}$ | $\begin{gathered} 6 \\ (1.2) \\ \hline \end{gathered}$ | $\begin{gathered} 0.7 \\ (0.3,1.5) \end{gathered}$ |
| Injection-site reactions | $\begin{gathered} 53 \\ (11.7) \end{gathered}$ | $\begin{gathered} 7.4 \\ (5.7,9.7) \\ \hline \end{gathered}$ | $\begin{gathered} 107 \\ (20.7) \end{gathered}$ | $\begin{gathered} 12.1 \\ (10.0,14.6) \end{gathered}$ |
| Mild | $\begin{gathered} 40 \\ (8.8) \\ \hline \end{gathered}$ | $\begin{gathered} 5.6 \\ (4.1,7.6) \\ \hline \end{gathered}$ | $\begin{gathered} 79 \\ (15.3) \\ \hline \end{gathered}$ | $\begin{gathered} 8.9 \\ (7.2,11.1) \\ \hline \end{gathered}$ |
| Moderate | $\begin{gathered} 12 \\ (2.6) \\ \hline \end{gathered}$ | $\begin{gathered} 1.7 \\ (1.0,3.0) \end{gathered}$ | $\begin{gathered} 23 \\ (4.4) \\ \hline \end{gathered}$ | $\begin{gathered} 2.6 \\ (1.7,3.9) \\ \hline \end{gathered}$ |
| Severe | $\begin{gathered} 1 \\ (0.2) \end{gathered}$ | $\begin{gathered} 0.1 \\ (0.0,1.0) \end{gathered}$ | $\begin{gathered} 5 \\ (1.0) \\ \hline \end{gathered}$ | $\begin{gathered} 0.6 \\ (0.2,1.4) \end{gathered}$ |
| Allergic reactions /hypersensitivities | $\begin{gathered} 37 \\ (8.1) \end{gathered}$ | $\begin{gathered} 5.2 \\ (3.8,7.2) \end{gathered}$ | $\begin{gathered} 46 \\ (8.9) \\ \hline \end{gathered}$ | $\begin{gathered} 5.2 \\ (3.9,6.9) \\ \hline \end{gathered}$ |
| Cytopenia | $\begin{gathered} 8 \\ (1.8) \end{gathered}$ | $\begin{gathered} 1.1 \\ (0.6,2.2) \end{gathered}$ | $\begin{gathered} 18 \\ (3.5) \\ \hline \end{gathered}$ | $\begin{gathered} 2.0 \\ (1.3,3.2) \end{gathered}$ |
| Neutropenia | $\begin{gathered} 4 \\ (0.9) \\ \hline \end{gathered}$ | $\begin{gathered} 0.6 \\ (0.2,1.5) \end{gathered}$ | $\begin{gathered} 8 \\ (1.5) \\ \hline \end{gathered}$ | $\begin{gathered} 0.9 \\ (0.5,1.8) \end{gathered}$ |
| Hepatic events | $\begin{gathered} 34 \\ (7.5) \end{gathered}$ | $\begin{gathered} 4.8 \\ (3.4,6.7) \end{gathered}$ | $\begin{gathered} 38 \\ (7.3) \\ \hline \end{gathered}$ | $\begin{gathered} 4.3 \\ (3.1,5.9) \end{gathered}$ |
| Malignancies | $\begin{gathered} 3 \\ (0.7) \end{gathered}$ | $\begin{gathered} 0.4 \\ (0.1,1.3) \end{gathered}$ | $\begin{gathered} 4 \\ (0.8) \\ \hline \end{gathered}$ | $\begin{gathered} 0.5 \\ (0.2,1.2) \end{gathered}$ |
| Depression | $\begin{gathered} 6 \\ (1.3) \end{gathered}$ | $\begin{gathered} 0.8 \\ (0.4,1.9) \end{gathered}$ | $\begin{gathered} 11 \\ (2.1) \end{gathered}$ | $\begin{gathered} 1.2 \\ (0.7,2.2) \end{gathered}$ |

${ }^{\text {a }}$ During COAST-X, 40 patients were switched from IXE Q4W to open-label IXE Q2W. Adverse events for these patients were counted for the dose regimen they were receiving when the AE occurred, thus these patients were counted in the total for both dose regimens. ${ }^{\text {b }}$ None of the 11 candidiasis infections were systemic.
Abbreviations: IR, incidence rate per 100 patient-years; IXE, ixekizumab; PY, patient-years; Q2W, every 2 weeks; Q4W, every 4 weeks; TEAE, treatment-emergent adverse event.

